Regulation of HLA class II expression prevents allogeneic T-cell responses

Tissue Antigens

Volumn 77, Issue 1, 2011, Pages 36-44

  Jaimes, Y ^a   Seltsam, A ^b   Eiz Vesper, B ^a   Blasczyk, R ^a   Figueiredo, C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Institut Springe   (Germany)

Author keywords

Allogeneic transplantation; Human leukocyte antigen DM; Human leukocyte antigen DR; RNA interference; Tolerance

Indexed keywords

ALLOANTIGEN; GAMMA INTERFERON; GRANZYME B; HLA ANTIGEN CLASS 2; HLA DM ANTIGEN; HLA DR ANTIGEN; MESSENGER RNA; SHORT HAIRPIN RNA; T LYMPHOCYTE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL STIMULATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE SILENCING; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; RNA INTERFERENCE; UPREGULATION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; HLA-D ANTIGENS; HUMANS; INTERFERON-GAMMA; T-LYMPHOCYTES;

EID: 78650000599     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2010.01576.x     Document Type: Article

References (59)

1. Hall BM. Cells mediating allograft rejection. Transplantation 1991: 51: 1141-51.
2. Bishop DK, Chan S, Li W, Ensley RD, Xu S, Eichwald EJ. CD4-positive helper T lymphocytes mediate mouse cardiac allograft rejection independent of donor alloantigen specific cytotoxic T lymphocytes. Transplantation 1993: 56: 892-7.
3. Koga S, Auerbach MB, Engeman TM, Novick AC, Toma H, Fairchild RL. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. J Immunol 1999: 163: 4878-85.
4. Schonemann C, Groth J, Leverenz S, May G. HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance. Transplantation 1998: 65: 1519-23.
5. Iniotaki-Theodoraki A, Douramani P, Boletis J et al. Immune reactivity toward HLA class II determinants in renal transplantation. Transplant Proc 2001: 33: 461-4.
6. Samaniego M, Mezrich J, Torrealba J et al. C4d-positive acute antibody-mediated rejection due to anti-HLA-DP antibody: a tale of one patient and a review of the University of Wisconsin experience. Clin Transpl 2006: 503-7.
7. Neefjes JJ, Stollorz V, Peters PJ, Geuze HJ, Ploegh HL. The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route. Cell 1990: 61: 171-83.
8. Jensen PE, Weber DA, Thayer WP, Chen X, Dao CT. HLA-DM and the MHC class II antigen presentation pathway. Immunol Res 1999: 20: 195-205.
9. Hornell TM, Beresford GW, Bushey A, Boss JM, Mellins ED. Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor. J Immunol 2003: 171: 2374-83.
10. Neumann J, Koch N. Assembly of major histocompatibility complex class II subunits with invariant chain. FEBS Lett 2005: 579: 6055-9.
11. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr Opin Immunol 1996: 8: 348-54.
12. Pieters J. MHC class II restricted antigen presentation. Curr Opin Immunol 1997: 9: 89-96.
13. Sherman MA, Weber DA, Spotts EA, Moore JC, Jensen PE. Inefficient peptide binding by cell-surface class II MHC molecules. Cell Immunol 1997: 182: 1-11.
14. Vogt AB, Kropshofer H. HLA-DM - an endosomal and lysosomal chaperone for the immune system. Trends Biochem Sci 1999: 24: 150-4.
15. Li M, Li H, Rossi JJ. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann N Y Acad Sci 2006: 1082: 172-9.
16. Chen CC, Ko TM, Ma HI et al. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther 2007: 14: 11-9.
17. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther 2006: 13: 464-77.
18. Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci 2006: 97: 689-96.
19. Raoul C, Barker SD, Aebischer P. Viral-based modelling and correction of neurodegenerative diseases by RNA interference. Gene Ther 2006: 13: 487-95.
20. Davidson BL, Boudreau RL. RNA interference: a tool for querying nervous system function and an emerging therapy. Neuron 2007: 53: 781-8.
21. Shen J, Samul R, Silva RL et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006: 13: 225-34.
22. Takanashi M, Oikawa K, Sudo K et al. Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. Gene Ther 2009: 16: 982-9.
23. Gould DS, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999: 20: 77-82.
24. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 2007: 109: 827-35.
25. Lechler R, Lombardi G. The structural basis of alloreactivity. Immunol Res 1990: 9: 135-46.
26. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993: 11: 385-402.
27. Watschinger B, Gallon L, Carpenter CB, Sayegh MH. Mechanisms of allo-recognition. Recognition by in vivo-primed T cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation 1994: 57: 572-6.
28. Afzali B, Lechler RI, Hernandez-Fuentes MP. Allorecognition and the alloresponse: clinical implications. Tissue Antigens 2007: 69: 545-56.
29. Hall BM, Dorsch SE. Cells mediating allograft rejection. Immunol Rev 1984: 77: 31-59.
30. Reznik SI, Jaramillo A, SivaSai KS et al. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant 2001: 1: 228-35.
31. Golshayan D, Buhler L, Lechler RI, Pascual M. From current immunosuppressive strategies to clinical tolerance of allografts. Transpl Int 2007: 20: 12-24.
32. Horn PA, Figueiredo C, Kiem HP. Gene therapy in the transplantation of allogeneic organs and stem cells. Curr Gene Ther 2007: 7: 458-68.
33. Figueiredo C, Seltsam A, Blasczyk R. Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery. J Mol Med 2006: 84: 425-37.
34. Figueiredo C, Goudeva L, Horn PA, Eiz-Vesper B, Blasczyk R, Seltsam A. Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion.
35. Figueiredo C, Horn PA, Blasczyk R, Seltsam A. Regulating MHC expression for cellular therapeutics. Transfusion 2007: 47: 18-27.
36. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996: 383: 787-93.
37. Kagi D, Seiler P, Pavlovic J et al. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol 1995: 25: 3256-62.
38. Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol 2000: 18: 275-308.
39. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 1998: 41: 2108-16.
40. Porakishvili N, Kardava L, Jewell AP et al. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 2004: 89: 435-43.
41. Allez M, Tieng V, Nakazawa A et al. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 2007: 132: 2346-58.
42. Figueiredo C, Wittmann M, Wang D et al. Heat shock protein 70 (HSP70) induces cytotoxicity of T-helper cells. Blood 2009: 113: 3008-16.
43. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002: 168: 5954-8.
44. Duftner C, Goldberger C, Falkenbach A et al. Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis. Arthritis Res Ther 2003: 5: R292-300.
45. Williams NS, Engelhard VH. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J Immunol 1996: 156: 153-9.
46. Echchakir H, Bagot M, Dorothee G et al. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 2000: 115: 74-80.
47. Yasukawa M, Ohminami H, Arai J, Kasahara Y, Ishida Y, Fujita S. Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. Blood 2000: 95: 2352-5.
48. Agarwal S, Rao A. Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity 1998: 9: 765-75.
49. Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR et al. Helper T cell differentiation is controlled by the cell cycle. Immunity 1998: 9: 229-37.
50. Oehen S, Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 1998: 161: 5338-46.
51. Rosato A, Zoso A, Dalla Santa S et al. Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8+ T cell parameters. J Immunol 2006: 176: 1999-2006.
52. Rosato A, Zoso A, Milan G et al. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy. J Immunol 2003: 171: 5172-9.
53. Tigno-Aranjuez JT, Lehmann PV, Tary-Lehmann M. Dissociated induction of cytotoxicity and DTH by CFA and CpG. J Immunother 2009: 32: 389-98.
54. Kuerten S, Nowacki TM, Kleen TO, Asaad RJ, Lehmann PV, Tary-Lehmann M. Dissociated production of perforin, granzyme B, and IFN-gamma by HIV-specific CD8(+) cells in HIV infection. AIDS Res Hum Retroviruses 2008: 24: 62-71.
55. Auphan-Anezin N, Verdeil G, Schmitt-Verhulst AM. Distinct thresholds for CD8 T cell activation lead to functional heterogeneity: CD8 T cell priming can occur independently of cell division. J Immunol 2003: 170: 2442-8.
56. Jaimes Y, Figueiredo C, Blasczyk R. Silencing the expression of platelet endothelial cell adhesion molecule-1 prevents allogeneic T-cell cytotoxicity. Transfusion.
57. Schambach A, Baum C. Clinical application of lentiviral vectors - concepts and practice. Curr Gene Ther 2008: 8: 474-82.
58. Pauwels K, Gijsbers R, Toelen J et al. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther 2009: 9: 459-74.
59. Melo LG, Pachori AS, Kong D et al. Gene and cell-based therapies for heart disease. FASAB J 2004: 18: 648-63.